WO2016019237A3 - Inhibiteurs de la tyrosine kinase de bruton - Google Patents

Inhibiteurs de la tyrosine kinase de bruton Download PDF

Info

Publication number
WO2016019237A3
WO2016019237A3 PCT/US2015/043102 US2015043102W WO2016019237A3 WO 2016019237 A3 WO2016019237 A3 WO 2016019237A3 US 2015043102 W US2015043102 W US 2015043102W WO 2016019237 A3 WO2016019237 A3 WO 2016019237A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
bruton
tyrosine kinase
methods
btk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/043102
Other languages
English (en)
Other versions
WO2016019237A2 (fr
Inventor
Wei Chen
Longcheng Wang
Zhaozhong J. Jia
James T. Palmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacyclics LLC
Original Assignee
Pharmacyclics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics LLC filed Critical Pharmacyclics LLC
Publication of WO2016019237A2 publication Critical patent/WO2016019237A2/fr
Publication of WO2016019237A3 publication Critical patent/WO2016019237A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés hétéroaryle contenant un groupe cyano qui sont utiles en tant qu'inhibiteurs des kinases. L'invention concerne également des procédés de synthèse de tels inhibiteurs et des méthodes d'utilisation de ces inhibiteurs dans le traitement de maladies.
PCT/US2015/043102 2014-07-31 2015-07-31 Inhibiteurs de la tyrosine kinase de bruton Ceased WO2016019237A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462031658P 2014-07-31 2014-07-31
US62/031,658 2014-07-31

Publications (2)

Publication Number Publication Date
WO2016019237A2 WO2016019237A2 (fr) 2016-02-04
WO2016019237A3 true WO2016019237A3 (fr) 2016-04-07

Family

ID=55218446

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/043102 Ceased WO2016019237A2 (fr) 2014-07-31 2015-07-31 Inhibiteurs de la tyrosine kinase de bruton

Country Status (1)

Country Link
WO (1) WO2016019237A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2976741C (fr) 2015-03-30 2023-01-17 Mission Therapeutics Limited Composes 1-cyano-pyrrolidine utilises comme inhibiteurs d'usp30
WO2016192074A1 (fr) * 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Inhibiteurs de la btk
CN108884068B (zh) * 2016-03-24 2021-02-26 特殊治疗有限公司 作为dub抑制剂的1-氰基-吡咯烷衍生物
WO2017198049A1 (fr) * 2016-05-16 2017-11-23 浙江予川医药科技有限公司 Dérivé de pyrazolopyrimidine utilisé en tant qu'inhibiteur de la btk et procédé de préparation et composition pharmaceutique associés
US10640512B2 (en) 2016-06-30 2020-05-05 Hangzhou Sanyintai Pharmaceutical Technology Co., Ltd. Imidazopyrazinamine phenyl derivative and use thereof
WO2018033091A1 (fr) * 2016-08-17 2018-02-22 深圳市塔吉瑞生物医药有限公司 Composé bicyclique fusionné pour inhiber l'activité de la tyrosine kinase
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
CN110831936B (zh) 2017-06-20 2023-03-28 特殊治疗有限公司 具有dub抑制剂活性的取代氰基吡咯烷
AU2018346597B2 (en) * 2017-10-06 2023-07-13 Forma Therapeutics, Inc. Inhibiting Ubiquitin Specific Peptidase 30
JP7449242B2 (ja) 2018-05-17 2024-03-13 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物
JP7530889B2 (ja) 2018-10-05 2024-08-08 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ３０（ｕｓｐ３０）阻害剤として作用する縮合ピロリン
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
CN111018865B (zh) * 2019-10-17 2021-01-15 山东大学 1-取代苄基吡唑并嘧啶衍生物及其制备方法与应用
AU2020436612A1 (en) * 2020-03-16 2022-09-01 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia
JP2023520727A (ja) 2020-04-08 2023-05-18 ミッション セラピューティクス リミティド Ｕｓｐ３０阻害剤として活性を有するｎ－シアノピロリジン
IL298526A (en) 2020-05-28 2023-01-01 Mission Therapeutics Ltd N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction
US20230303547A1 (en) 2020-06-04 2023-09-28 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
DK4161929T3 (da) 2020-06-08 2025-08-18 Mission Therapeutics Ltd 1-(5-(2-cyanopyridin-4-yl)oxazol-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrol-5(1h)-carbonitril som usp30-hæmmer til anvendelse i behandling af mitokondriedysfunktion, cancer og fibrose
CN114075190A (zh) * 2020-08-20 2022-02-22 北京诺诚健华医药科技有限公司 杂环类btk抑制剂
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
CN114573586B (zh) * 2020-11-28 2023-11-03 杭州和正医药有限公司 一种抑制布鲁顿酪氨酸激酶活性的多环化合物、药物组合物及其应用
CN113968860B (zh) * 2021-11-05 2023-06-06 杭州医学院 一种可逆btk抑制剂及其合成方法和应用
JP2024544660A (ja) 2021-12-01 2024-12-03 ミッション セラピューティクス リミティド Ｕｓｐ３０阻害剤としての活性を有する置換ｎ－シアノピロリジン
GB202408928D0 (en) 2024-06-21 2024-08-07 Mission Therapeutics Ltd Novel compounds
GB202411060D0 (en) 2024-07-29 2024-09-11 Mission Therapeutics Ltd Novel compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080076921A1 (en) * 2006-09-22 2008-03-27 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20090286768A1 (en) * 2008-05-19 2009-11-19 Osi Pharmaceuticals, Inc. Substituted imidazopyr- and imidazotri-azines
WO2014068527A1 (fr) * 2012-11-02 2014-05-08 Pfizer Inc. Inhibiteurs de la tyrosine kinase de bruton

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080076921A1 (en) * 2006-09-22 2008-03-27 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20090286768A1 (en) * 2008-05-19 2009-11-19 Osi Pharmaceuticals, Inc. Substituted imidazopyr- and imidazotri-azines
WO2014068527A1 (fr) * 2012-11-02 2014-05-08 Pfizer Inc. Inhibiteurs de la tyrosine kinase de bruton

Also Published As

Publication number Publication date
WO2016019237A2 (fr) 2016-02-04

Similar Documents

Publication Publication Date Title
WO2016019237A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
ZA202401324B (en) Tyrosine kinase inhibitors
WO2016004305A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
WO2016196776A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
WO2015195848A8 (fr) Inhibiteurs de ezh2 utilisables à des fins de traitement du lymphome
WO2015112806A3 (fr) Macrocycles de diaryle en tant que modulateurs de protéines kinases
EP3484504A4 (fr) Composés, compositions et méthodes de traitement de maladie
EP3265084A4 (fr) Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton
PH12017500802A1 (en) Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
CA2956871C (fr) Composes actifs envers des bromodomaines
WO2015193740A3 (fr) Combinaisons thérapeutiques d'un inhibiteur de la tkb, d'un inhibiteur de la pi3k et/ou d'un inhibiteur de la jak-2
PH12016501107B1 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
WO2015048689A8 (fr) Inhibiteurs de la tyrosine kinase de bruton
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
HK1252425A1 (zh) 用於治疗脱髓鞘疾病的三唑类药物
HK1251481A1 (zh) 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法
WO2016109217A3 (fr) Inhibiteurs de la btk
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
WO2015171558A3 (fr) Benzènesulfonamido et composés apparentés utilisés en tant qu'agonistes de rorγ et pour le traitement de maladie
EP3337482A4 (fr) Formulations transdermiques pour l'administration de composés de berbérine et leur utilisation dans le traitement de maladies et de pathologies sensibles à la berbérine
EP3093023A4 (fr) Composition pharmaceutique pour le traitement du cancer et préparation pharmaceutique pour le traitement du cancer contenant ladite composition en tant que substance active
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
MX2016005174A (es) Composiciones para uso en la prevencion y el tratamiento de enfermedades neurodegenerativas y dolor.
ZA202007320B (en) Compounds for pain treatment, compositions comprising same, and methods of using same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15827074

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15827074

Country of ref document: EP

Kind code of ref document: A2